98%
921
2 minutes
20
Unlabelled: It is unclear how to optimize the user interface and user experience of cancer screening artificial intelligence (AI) tools for clinical decision-making in primary care. We developed an electronic survey for US primary care clinicians to assess 1) general attitudes toward AI in cancer screening and 2) preferences for various aspects of AI model deployment in the context of colorectal, breast, and lung cancer screening. We descriptively analyzed the responses. Ninety-nine surveys met criteria for analysis out of 733 potential respondents (response rate 14%). Ninety (>90%) somewhat or strongly agreed that their medical education did not provide adequate AI training. A plurality (52%, 39%, and 37% for colon, breast, and lung cancers, respectively) preferred that AI tools recommend the interval to the next screening as compared with the 5-y probability of future cancer diagnosis, a binary recommendation of "screen now," or identification of suspicious imaging findings. In terms of workflow, respondents preferred generating a flag in the electronic health record to communicate an AI prediction versus an interactive smartphone application or the delegation of findings to another healthcare professional. No majority preference emerged for an explainability method for breast cancer screening. The sample was primarily obtained from a single health care system in the Northeast. Providers indicated that AI models can be most helpful in cancer screening by providing prescriptive outputs, such as recommended intervals until next screening, and by integrating with the electronic health record. A preliminary framework for AI model development in cancer screening may help ensure effective integration into clinical workflow. These findings can better inform how healthcare systems govern and receive reimbursement for services that use AI.
Highlights: Clinicians do not feel their undergraduate or graduate medical education has properly prepared them to engage with AI in patient care.We provide a preliminary framework for deploying AI models in primary care-based cancer screening.This framework may have implications for health system governance and provider reimbursement in the age of AI.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970086 | PMC |
http://dx.doi.org/10.1177/23814683251329007 | DOI Listing |
Mol Cancer Ther
September 2025
Case Western Reserve University School of Medicine, Cleveland, OH, United States.
The estrogen receptor (ER or ERα) remains the primary therapeutic target for luminal breast cancer, with current treatments centered on competitive antagonists, receptor down-regulators, and aromatase inhibitors. Despite these options, resistance frequently emerges, highlighting the need for alternative targeting strategies. We discovered a novel mechanism of ER inhibition that targets the previously unexplored interface between the DNA-binding domain (DBD) and ligand-binding domain (LBD) of the receptor.
View Article and Find Full Text PDFDiagn Interv Radiol
September 2025
LMU University Hospital, LMU Munich, Department of Radiology, Munich, Germany.
Purpose: Computed tomography fluoroscopy (CTF)-guided biopsy is an established technique for sampling pulmonary lesions, particularly with the growing prevalence of lung nodule screening programs. This study investigated procedural and lesion-related factors affecting success and complication rates in routine CTF-guided lung core-needle biopsies at a tertiary center.
Methods: Consecutive patients undergoing percutaneous CTF-guided lung biopsies over a 10-year period (2007-2016) were retrospectively analyzed.
Chembiochem
September 2025
School of Biological and Chemical Sciences, Ryan Institute, University of Galway, University Road, Galway, H91 TK33, Ireland.
Activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL) is an aggressive cancer with poor response to standard chemotherapy. In search of new therapeutic leads, a library of 435 fractions prepared from the Irish marine biorepository was screened against 2 ABC-DLBCL cell lines (TMD8 and OCI-Ly10) and a non-cancerous control cell line (CB33). Active fractions are prioritized based on potency and selectivity.
View Article and Find Full Text PDFPeriodontol 2000
September 2025
Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Oral cancer is a major global health burden, ranking sixth in prevalence, with oral squamous cell carcinoma (OSCC) being the most common type. Importantly, OSCC is often diagnosed at late stages, underscoring the need for innovative methods for early detection. The oral microbiome, an active microbial community within the oral cavity, holds promise as a biomarker for the prediction and progression of cancer.
View Article and Find Full Text PDFChembiochem
September 2025
School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, P. R. China.
The ATPase caseinolytic protease X (ClpX), forming the ClpXP complex with caseinolytic protease P (ClpP), is essential for mitochondrial protein homeostasis. While ClpP targeting is a recognized anticancer strategy, the role of ClpX in cancer remains underexplored. In pancreatic ductal adenocarcinoma (PDAC), elevated CLPX expression correlates with poor prognosis, suggesting its oncogenic function.
View Article and Find Full Text PDF